They did multiple raisings at the same price with no step up in value and hence no rise in valuation which shows the blatant disregard the management has for shareholder capital.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025